ESPR Settles Nexletol/Nexlizet Patent Litigation With RDY, Stock Up

Key Takeaways Esperion reached a settlement with Dr. Reddy's over patents for Nexletol and Nexlizet.RDY agreed not to launch U.S. generics of the drugs before April 19, 2040, under the deal.The settlement resolves remaining disputes with RDY tied to Esperion's key bempedoic acid patent.Esperion Therapeutics (ESPR) announced that it has entered into a settlement agreement with Dr. Reddy’s Laboratories (RDY) related to patents for the marketed drugs, Nexletol (bempedoic acid) and Nexlizet (bempedoic acid and ...